VIRAL MODULATION OF EPITHELIAL FUNCTION

上皮功能的病毒调节

基本信息

  • 批准号:
    6338614
  • 负责人:
  • 金额:
    $ 20.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-01 至 2001-08-31
  • 项目状态:
    已结题

项目摘要

This Program Grant focuses on the hypothesis that chronic rhinosinusitis, a disease affects approximately 15% of Americans, is due to epithelial cell dysfunction. This dysfunction may arise from an inherent genetic defect(s), environmental influences, or most likely, a combination of the two. This project contributes to this hypothesis by testing whether viral infection is an important environmental stimulus in the development and exacerbation of chronic rhinosinusitis by triggering alterations in epithelial cell function, particularly increased production of pro- inflammatory cytokines, including IL-8, GM-CSF, RANTES and eotaxin. To examine the relationship between viral infection and chronic rhinosinusitis we will monitor subjects prospectively following endoscopic sinus surgery to determine if nasal and sinus secretions from subjects experiencing exacerbations of rhinosinusitis show a higher incidence of viral infection, detected by PCR, compared to secretions obtained from the same subjects during periods when disease activity is less severe. Given that nitric oxide (NO), is antiviral and inhibits epithelial cytokine production, we also will test the hypothesis that an inability of the sinus epithelium to increase production of NO, via the enzyme inducible NO synthase (iNOS), during viral infections is a risk factor for chronic rhinosinusitis. We will examine the mechanism of induction of iNOS by rhinovirus in cultured epithelial cells and will determine if subjects with chronic rhinosinusitis show lower induction of epithelial iNOS expression, and increased epithelial cytokine production and inflammation, compared to normal subjects during experimental rhinovirus infections. Intranasal glucocorticoids are currently advocated as an appropriate therapy to reduce disease recurrence in patients after sinus surgery. Despite widespread use for this identification, however, the efficacy, and mechanisms glucocorticoids versus placebo in subjects recruited after sinus injury to test the hypothesis, which is based upon in vitro data, that topical glucocorticoids will reduce epithelial expression of GM-CSF, RANTES, and eotaxin, and tissue eosinophilia in subjects but will have little effect on epithelial expression of IL-8 or on neutrophilic inflammation. We suggest that such an outcome will result in only a partial therapeutic effect. These studies should provide important insights into the pathogenesis of chronic rhinosinusitis and may lead to the development of improved therapies for the treatment of this major health problem.
这个项目资助的重点是慢性鼻窦炎的假设,这种疾病影响了大约15%的美国人,是由于上皮细胞功能障碍。这种功能障碍可能是由固有的遗传缺陷、环境影响或最可能的是两者的结合引起的。该项目通过测试病毒感染是否是慢性鼻窦炎发生和恶化的重要环境刺激因素,通过触发上皮细胞功能的改变,特别是增加促炎细胞因子的产生,包括IL-8、GM-CSF、RANTES和eotaxin,来支持这一假设。为了研究病毒感染与慢性鼻窦炎之间的关系,我们将在鼻窦内窥镜手术后对受试者进行前瞻性监测,以确定与同一受试者在疾病活动不那么严重的时期获得的分泌物相比,经历鼻窦炎加重的受试者的鼻和鼻窦分泌物是否显示出更高的病毒感染发生率。鉴于一氧化氮(NO)具有抗病毒作用并抑制上皮细胞因子的产生,我们也将验证鼻窦上皮在病毒感染期间无法通过酶诱导NO合成酶(iNOS)增加NO的产生是慢性鼻窦炎的危险因素这一假设。我们将研究鼻病毒在培养的上皮细胞中诱导iNOS的机制,并确定在实验鼻病毒感染期间,与正常受试者相比,慢性鼻窦炎受试者是否表现出较低的上皮iNOS诱导表达,以及上皮细胞因子的产生和炎症的增加。鼻内糖皮质激素目前被提倡作为一种适当的治疗方法来减少鼻窦手术后患者的疾病复发。然而,尽管这种鉴定被广泛使用,但在窦损伤后招募的受试者中,糖皮质激素与安慰剂的疗效和机制验证了基于体外数据的假设,即局部糖皮质激素会降低受试者中GM-CSF、RANTES和eotaxin的上皮表达以及组织嗜酸性粒细胞,但对上皮表达IL-8或嗜中性粒细胞炎症几乎没有影响。我们认为这样的结果只会产生部分治疗效果。这些研究应该为慢性鼻窦炎的发病机制提供重要的见解,并可能导致改进治疗这一主要健康问题的疗法的发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Proud其他文献

David Proud的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Proud', 18)}}的其他基金

VIRAL MODULATION OF EPITHELIAL FUNCTION
上皮功能的病毒调节
  • 批准号:
    6201225
  • 财政年份:
    1999
  • 资助金额:
    $ 20.91万
  • 项目类别:
EPITHELIAL FUNCTION AND DYSFUNCTION IN CHRONIC SINUSITIS
慢性鼻窦炎的上皮功能和功能障碍
  • 批准号:
    6281959
  • 财政年份:
    1998
  • 资助金额:
    $ 20.91万
  • 项目类别:
VIRAL INFECTIONS IN EPITHELIAL FUNCTION
病毒感染对上皮功能的影响
  • 批准号:
    6099868
  • 财政年份:
    1998
  • 资助金额:
    $ 20.91万
  • 项目类别:
APPLIED BIOSYSTEMS MODEL 7700 01 SEQUENCE DETECTOR
应用生物系统 7700 01 型序列检测器
  • 批准号:
    2503055
  • 财政年份:
    1998
  • 资助金额:
    $ 20.91万
  • 项目类别:
EPITHELIAL FUNCTION AND DYSFUNCTION IN CHRONIC SINUSITIS
慢性鼻窦炎的上皮功能和功能障碍
  • 批准号:
    6121419
  • 财政年份:
    1998
  • 资助金额:
    $ 20.91万
  • 项目类别:
VIRAL INFECTIONS IN EPITHELIAL FUNCTION
病毒感染对上皮功能的影响
  • 批准号:
    6235287
  • 财政年份:
    1997
  • 资助金额:
    $ 20.91万
  • 项目类别:
EPITHELIAL FUNCTION AND DYSFUNCTION IN CHRONIC SINUSITIS
慢性鼻窦炎的上皮功能和功能障碍
  • 批准号:
    6029874
  • 财政年份:
    1995
  • 资助金额:
    $ 20.91万
  • 项目类别:
EPITHELIAL FUNCTION AND DYSFUNCTION IN CHRONIC SINUSITIS
慢性鼻窦炎的上皮功能和功能障碍
  • 批准号:
    2517274
  • 财政年份:
    1995
  • 资助金额:
    $ 20.91万
  • 项目类别:
EPITHELIAL FUNCTION AND DYSFUNCTION IN CHRONIC SINUSITIS
慢性鼻窦炎的上皮功能和功能障碍
  • 批准号:
    2073798
  • 财政年份:
    1995
  • 资助金额:
    $ 20.91万
  • 项目类别:
EPITHELIAL FUNCTION AND DYSFUNCTION IN CHRONIC SINUSITIS
慢性鼻窦炎的上皮功能和功能障碍
  • 批准号:
    2672429
  • 财政年份:
    1995
  • 资助金额:
    $ 20.91万
  • 项目类别:

相似国自然基金

Chemokine-Gli2信号环路调控肝癌生长的分子机制及其靶点价值
  • 批准号:
    81660467
  • 批准年份:
    2016
  • 资助金额:
    39.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Atypical Chemokine Receptors orchestrate changes in vascular patterning during fibrotic liver disease via Endothelial-to-Mesenchymal Transition.
非典型趋化因子受体通过内皮-间质转化协调纤维化肝病期间血管模式的变化。
  • 批准号:
    MR/Y013751/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Research Grant
Potential role of chemokine (C-C motif) ligand 18 in the development of obese asthma and Type 2 inflammation using epidemiological and experimental studies
使用流行病学和实验研究发现趋化因子(C-C 基序)配体 18 在肥胖哮喘和 2 型炎症发展中的潜在作用
  • 批准号:
    23K09664
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regulation of chemokine receptor signaling
趋化因子受体信号传导的调节
  • 批准号:
    10622915
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Structure-based inhibition of chemokine signaling in the inflamed pancreas
基于结构的炎症胰腺趋化因子信号传导抑制
  • 批准号:
    10656002
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
  • 批准号:
    478877
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Operating Grants
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
PET 成像评估新型趋化因子拮抗剂保护 ADRD 突触
  • 批准号:
    10818903
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Development of A Dual Chemokine CCL2/CCL5 Neutralizing Single-domainAntibody for Treating Non-alcoholic Steatohepatitis
双趋化因子 CCL2/CCL5 中和单域抗体的开发用于治疗非酒精性脂肪性肝炎
  • 批准号:
    10761039
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Mechanism of metastatic control by chemokine receptor ACKR3
趋化因子受体ACKR3控制转移的机制
  • 批准号:
    23K06639
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrated Imaging Tools for Intercellular Chemokine Signalling
用于细胞间趋化因子信号转导的集成成像工具
  • 批准号:
    10706896
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了